According to a recent analysis by Emergent Research, the global market for direct-to-consumer genetic testing is anticipated to reach USD 3.33 billion by 2027. A rise in the prevalence of genetic diseases will spur competition in direct-to-consumer genetic testing and hasten market growth throughout the anticipated period. The need for affordable and dependable methods of genetic testing in the healthcare sector has increased due to the rise in the incidence of hereditary disorders like breast cancer, achondroplasia, colorectal cancer, and other diseases.
The DTC genetic testing market is fragmented, with a small number of prominent firms and other new, tiny start-up businesses offering higher quality DTC tests at cheaper prices that will address affordability difficulties and favorably affect market growth. The direct-to-consumer genetic testing market was positively impacted by the COVID-19 pandemic. As a result of technological advancements during the pandemic, new economic prospects in direct-to-consumer genetic testing have emerged. The rise in the prevalence of chronic diseases and the arrival of individualized testing kits for specialized therapeutic fields have both contributed to the rapid growth of direct-to-consumer genetic testing. The demand for these kits has increased as a result of these service adaptations and changes. Additionally, the fact that these kits are accessible through online platform services would have a favorable impact on market statistics.
For reference, more than 2 million new cancer cases were reported globally in 2018, according to the World Cancer Research Fund (WCRF). Today, breast cancer is ranked as the second most common disease. A higher standard and cutting-edge direct-to-consumer genetic testing have dramatically reduced mortality rates among people.
Further key findings from the report suggest
- Based on test type, carrier testing generated USD 139.21 million in revenue in 2019 and is anticipated to increase with a CAGR of 13.2 percent in the forecast period. It is used by fertility planners to determine whether a person is a carrier of specific recessive autosomal diseases, which helps them predict the likelihood that genetic defects will be passed on to their offspring.
- Due to the ease of acquiring a test kit for customers living in developed world rural areas, as enforcement authorities inspect them individually to make them easier to acquire, the over-the-counter channel is predicted to rise with a CAGR of 12.8 percent in the forecasted period.
- The Direct-to-Consumer Genetic Testing Market’s largest contributor is the single nucleotide polymorphism chips application. Because it can identify various variations in a distinct letter to improve test performance, the single nucleotide polymorphism chips application from the North American area holds a significant part of the market, accounting for about 47.7% of it in 2019.
- The following companies are significant participants: 23andMe, Full Genome Corporation, Color Genomics, Genesis Healthcare, Helix OpCo LLC, FamilyTreeDNA, MyHeritage, Identigene, Pathway genomics, and Living DNA.
For this report, Emergen Research has segmented into the global Direct-to-Consumer Genetic Testing market based on the test type, distribution channel, application, and region:
Test Type Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Billion; 2017-2027)
- Carrier Testing
- Predictive Testing
- Ancestry & Relationship Testing
- Nutrigenomics Testing
Distribution Channel Outlook (Volume, Kilotons; 2017-2027, Revenue, USD Billion; 2017-2027)
- Online Platforms
Application Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Billion; 2017-2027)
- Targeted Analysis
- Single Nucleotide Polymorphism Chips (SNP)
- Whole Genome Sequencing (WGS)
Regional Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Billion; 2017-2027)
- North America
- the UK
- Rest of Europe
- the Asia Pacific
- South Korea
- Rest of APAC
- Saudi Arabia
- Rest of MEA
- Latin America
- Rest of LATAM